Replies to post #340 on Equity Field Notes from temporal sources

[DanWebzster]

CBIO is a clinical stage biotech focused on the treatment of Hemophilia trading around cash.

Data from its lead Hemophilia A or B program is expected at ASH 2018.

The advantages of this treatment over the infusion treatments are:
* Easy subcutaneous injections
* Potential for home therapy
* Fewer bleeds
* Prevention of muscle/joint damage

If approved, this treatment would compete with treatments from Shire, NVO, APVO & Sanofi. Despite, this the efficacy of CBIO's lead treatment makes 25% market share seem achievable.